OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

Unlimited access to all stories from nashuatelegraph.com on your computer, tablet or smart phone. Access nashuatelegraph.com, view our digital edition or use our Full ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon ... a once-daily tablet, combines OPKO's ...

According to Cleveland Clinic, most of the GLP-1 agonists are available as liquid medication that needs to be injected under the skin, except one that is available in tablet form (Rybelsus).

Oxford Medical Products today announces additional three-month clinical trial results for Sirona, a weight-loss treatment targeting people who are overweight or have class I obesity (BMI 25-35) and ...

Opko Health Inc. and Entera Bio Ltd. have entered into a collaboration and license agreement to advance an oral dual agonist GLP-1/glucagon peptide as a once-daily tablet into the clinic for patients ...